Systemic corticosteroid for prophylaxis of postembolization syndrome after Hepatic Transarterial Chemoembolization in patients with hepatocellular carcinoma: A randomized, double-blinded, placebo controlled trial
Phase 2
Completed
- Conditions
- Hepatocellular carcinoma patients who eligible for Tranarterial chemoembolization.HCC TACE prophylaxis steroid
- Registration Number
- TCTR20170906004
- Lead Sponsor
- /A
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Hepatocellular carcinoma patients who eligible for Tranarterial chemoembolization.
Exclusion Criteria
1.patient with Child-Pugh class C
2.patient with active upper gastrointestinal bleeding
3. patient with metastatic HCC
4. patient with encephalopathy
5. patient with refractory ascites
6. patient with intrahepatic duct dilatation
7.patient with TB > 2 mg/dl
8. patient with major portal vein thrombosis
9.patient who is not eligible for TACE
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Effectiveness of dexamethasone in prevention of postembolization syndrome 48 hours after intervention Southwest oncology group toxicity coding score
- Secondary Outcome Measures
Name Time Method Duration of hospitalization between groups at least 1 week after intervention hospitalized duration in day